Nicola Urbani has 14 years of experience in venture capital investments, primarily in life sciences and cleantech, with two different venture capital groups, GeneChem Management and Emerillon Capital. He has served on numerous Boards and helped shape company strategies, C-level management teams, and Board committees. Nicola had an active involvement in the growth of several companies developing therapeutics through human clinical trials and participated in numerous financing rounds with top-tier International and Canadian venture capital funds. Nicola has also led several in-and out-licensing deals in life sciences and cleantech.
Before joining Emerillon, Nicola was the VP Commercialization at the McGill-affiliated Jewish General Hospital in Montreal, where he was responsible for technology transfer and creating start-up companies. Nicola has a Ph.D. in molecular genetics from McGill University and an MBA from Université du Québec à Montréal.